Drugs / CpG oligodeoxynucleotide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00640861 | Aug 2008 → Apr 2015 | female breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CpG oligodeoxynucleotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00640861 ↗ |
| Modality | Oligonucleotide (other) | “CpG oligodeoxynucleotide” NCT00640861 ↗ |
| Route | Subcutaneous | “Patients receive a vaccine comprising incomplete Freund's adjuvant, MUC1 antigen vaccine, two Her-2/neu peptide-based vaccines (one of them different than in arm A), and CpG...” NCT00640861 ↗ |